Literature DB >> 19916793

The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration.

Surang Leelawat1, Kawin Leelawat, Siriluck Narong, Oraphan Matangkasombut.   

Abstract

Currently, only gemcitabine plus platinum demonstrates the considerable activity for cholangiocarcinoma. The anticancer effect of Delta (9)-tetrahydrocannabinol (THC), the principal active component of cannabinoids has been demonstrated in various kinds of cancers. We therefore evaluate the antitumor effects of THC on cholangiocarcinoma cells. Both cholangiocarcinoma cell lines and surgical specimens from cholangiocarcinoma patients expressed cannabinoid receptors. THC inhibited cell proliferation, migration and invasion, and induced cell apoptosis. THC also decreased actin polymerization and reduced tumor cell survival in anoikis assay. pMEK1/2 and pAkt demonstrated the lower extent than untreated cells. Consequently, THC is potentially used to retard cholangiocarcinoma cell growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19916793     DOI: 10.3109/07357900903405934

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  7 in total

1.  Δ(9) Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells.

Authors:  R Rao; P S Nagarkatti; M Nagarkatti
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

2.  Decisive role of P42/44 mitogen-activated protein kinase in Δ9-tetrahydrocannabinol-induced migration of human mesenchymal stem cells.

Authors:  Ellen Lüder; Robert Ramer; Kirsten Peters; Burkhard Hinz
Journal:  Oncotarget       Date:  2017-11-20

3.  Compromised External Validity: Federally Produced Cannabis Does Not Reflect Legal Markets.

Authors:  Daniela Vergara; L Cinnamon Bidwell; Reggie Gaudino; Anthony Torres; Gary Du; Travis C Ruthenburg; Kymron deCesare; Donald P Land; Kent E Hutchison; Nolan C Kane
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

4.  Antitumor Effects of Cannabinoids in Human Pancreatic Ductal Adenocarcinoma Cell Line (Capan-2)-Derived Xenograft Mouse Model.

Authors:  Siriwan Sakarin; Nuntana Meesiripan; Suleeporn Sangrajrang; Nuntakan Suwanpidokkul; Piyaporn Prayakprom; Chatchada Bodhibukkana; Vipada Khaowroongrueng; Kankanit Suriyachan; Somchai Thanasittichai; Attasit Srisubat; Pattamaporn Surawongsin; Kasem Rattanapinyopituk
Journal:  Front Vet Sci       Date:  2022-07-22

5.  A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas.

Authors:  Janet Schloss; Judith Lacey; Justin Sinclair; Amie Steel; Michael Sughrue; David Sibbritt; Charles Teo
Journal:  Front Oncol       Date:  2021-05-21       Impact factor: 6.244

Review 6.  Cannabinoids as anticancer drugs: current status of preclinical research.

Authors:  Burkhard Hinz; Robert Ramer
Journal:  Br J Cancer       Date:  2022-03-11       Impact factor: 9.075

Review 7.  Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma.

Authors:  Hector Perez-Montoyo
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.